AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04129710
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral lenalidomide 25mg/day between days 4 and 24 of each cycle for six cycles. Then lenalidomide is continued until disease progression, intolerable toxicity, death or up to two years.
Trial: NCT04129710
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m2 conventional infusion on day 1
Trial: NCT04129710
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide 250 mg/m2 over 3 hours on day3
Trial: NCT02970526
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intensity of neuropathy induced by oxaliplatin evaluated by the QLQ-CIPN20 Questionnaire (EORTC).
Trial: NCT01271257
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 microgram PO per hour for 8 doses or 80 microgram PO per 4 hours for 2 doses
Trial: NCT00490022
Drug: Dihydrotestosterone (DHT) gel (0.7%)
RxNorm normalized name: 2α-Methyl-4,5-dihydrotestosterone propionate
DrugBank: Stanolone (DB02901)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHT gel, 70 mg/day for one month
Trial: NCT02986100
Drug: C-14 labeled Rucaparib
RxNorm normalized name: Tipranavir C-14
DrugBank: Rucaparib (DB12332)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Each dosage unit consists of a hard gelatin capsule filled with cold rucaparib camsylate and \[14C\]-rucaparib camsylate salt. Each capsule contains approximately 150 mg rucaparib (free base weight) and approximately 35 µCi of \[14C\]-rucaparib. Each patient will ingest four capsules in the fasted state for a total dose of 600 mg rucaparib (free base weight) with approximately 140 µCi of \[14C\]-rucaparib
Trial: NCT02986100
Drug: Rucaparib
RxNorm normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 200 \& 300 mg tablet
Trial: NCT00166491
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00913614
Drug: Eplivanserin (SR46349)
RxNorm normalized name: Eplivanserin
DrugBank: Eplivanserin (DB12177)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT00114023
Drug: Imiquimod 5% cream
RxNorm normalized name: IMIQUIMOD 5% CREAM,TOP,PKT,0.25GM
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01638104
Drug: ANX-042
RxNorm normalized name: hydroxyzine hydrochloride Oral Tablet [Anx]
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)
Trial: NCT03263780
Drug: 18F-Fluciclovine
RxNorm normalized name: fluciclovine (18F)
DrugBank: Fluciclovine (18F) (DB13146)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Imaging (comparing standard and experimental high resolution diffusion-weighted imaging \[DWI\] MRI with 18F-Fluciclovine)
Trial: NCT02011490
Drug: sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sugammadex 4 mg/kg IV bolus
Trial: NCT02421913
Drug: S(+)-Ketamine
RxNorm normalized name: (S)-ketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: S(+)-Ketamine 0,3mg/kg/hr intraoperative
Trial: NCT01869413
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid will be administered as an intravenous infusion of 10 mg/kg over 10 minutes (loading dose) prior to surgical incision, followed by 5 mg/kg/hour continuous maintenance infusion for the length of surgery (typically 4 to 8 hours).
Trial: NCT01355796
Drug: Xylitol
RxNorm normalized name: Xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosolized 15% xylitol, 5 ml twice a day for 2 weeks
Trial: NCT00801060
Drug: Lumiliximab + FCR
RxNorm normalized name: Lumiliximab
DrugBank: Lumiliximab (DB06162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose, schedule, and duration in the protocol
Trial: NCT00801060
Drug: FCR
RxNorm normalized name: FCR001
DrugBank: FCR001 (DB18595)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage, schedule, and duration in the protocol
Trial: NCT00860015
Drug: Alimta
RxNorm normalized name: Alimta
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg/m2 via IV over 10 minutes~A chemotherapy drug with indications to treat pleural mesothelioma and non-small cell lung cancer.
Trial: NCT00860015
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 via IV over 90 minutes~A nucleoside analog used as chemotherapy.
Trial: NCT03493789
Drug: Fludeoxyglucose F-18
RxNorm normalized name: Fludeoxyglucose F-18
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02973776
Drug: LEO 90100 aerosol foam
RxNorm normalized name: budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02973776
Drug: Diprosone
RxNorm normalized name: Diprosone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02973776
Drug: Elocon
RxNorm normalized name: Elocon
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02973776
Drug: Locoid
RxNorm normalized name: Locoid
DrugBank: Hydrocortisone butyrate (DB14540)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01407523
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * Formulation: concentrate for solution for infusion~* Strength: Levetiracetam injection (100 mg/mL) will be packed in 5 mL glass vials (500 mg/5 mL)~* Dosage: 1000 mg/day, 1500 mg/day, 2000 mg/day, 2500 mg/day or 3000 mg/day~* Frequency: twice daily
Trial: NCT03447093
Drug: Methimazole Pill
RxNorm normalized name: methimazole Pill
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who developed GD received methimazole treatment
Trial: NCT01522404
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in this intervention will receive Atomoxetine up to 29 weeks, crossover, dose escalating (up to a maximum dose of 100 mg per day) of oral atomoxetine
Trial: NCT03190694
Drug: Dapagliflozin 10mg
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet
Trial: NCT01349062
Drug: Kallunk oxide (Immunotherapy) 
RxNorm normalized name: Ferrosoferric Oxide
DrugBank: Ferric sulfate (DB11171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study is assigned Arm 1 above 450 cu/mm\^3 baseline CD + T cells. HIV type-1 subjects will receive one drug, a daily regimen of Kallunk oxide(Immunotherapy) + Long Pepper, that is a combination of a traditional alternative medicine (Complementary and Alternative Medicine CAM) as Kallunk oxide and appropriate drug carrier antidote. The drug assigns to 5 mg Kallunk oxide molecules with1995 mg Antidote( This antidote was used as a carrier of Kallunk oxide molecules), respectively, for children and adults. Dosage: 2000 mg for children and adults. This powder form sample size product will be administered once daily dose on 7 days treatment. The Botanical name of the antidote is Piper Longum.
Trial: NCT05840692
Drug: Escitalopram 20 mg
RxNorm normalized name: escitalopram 20 MG
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antidepressant
Trial: NCT01591863
Drug: fidaxomicin
RxNorm normalized name: Fidaxomicin
DrugBank: Fidaxomicin (DB08874)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 months-5 years 11 months: oral suspension, 32 mg/kg/day with a maximum dose of 400 mg/day, divided into two doses, every 12 hours for 10 days.~6 years-17 years 11 months: tablets, 200 mg every 12 hours for 10 days.
Trial: NCT00499902
Drug: alfimeprase
RxNorm normalized name: Alfimeprase
DrugBank: Alfimeprase (DB04919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfimeprase will be given as a single bolus of 1mg/2mL, or a split bolus of 5mg/2mL or 10mg/2mL in a three-tier dose escalation format. The 5mg and 10mg doses will be administered as split doses with 1/2 of the total dose given initially and 1/2 of the total dose given 30 minutes after the initial dose.
Trial: NCT02012088
Drug: RCHOP
RxNorm normalized name: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Day 1: Rituximab 375 mg/m2; Doxorubicin 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
Trial: NCT02017561
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin treatment titrated to a maximum dose of 1000mg twice a day. Metformin treatment will start with 500mg at breakfast during the first week and, if well tolerated, increased to 500mg twice a day (breakfast and dinner) in the second week, 1000mg at breakfast and 500mg at dinner in the third week and finally for the target dose of 1000mg twice a day.
Trial: NCT01495520
Drug: Ranolazine
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: os, pill, 750 mg, b.i.d., 30 days
Trial: NCT00513955
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00513955
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00162240
Drug: Muraglitazar
RxNorm normalized name: Muraglitazar
DrugBank: Muraglitazar (DB06510)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02794389
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02177513
Drug: Oral Cannabis + Placebo
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will consume a brownie containing the equivalent of one active (6.9% THC) cannabis cigarette followed by either smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
Trial: NCT02177513
Drug: Placebo + Inhaled Cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette
Trial: NCT02177513
Drug: Placebo + Smoked Cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking the equivalent of one active (6.9% THC) cigarette.
Trial: NCT00861016
Drug: metoprolol succinate prolonged-release tablet and felodipine
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a regimen that starts with metoprolol succinate prolonged-release tablet 47.5mg once daily, orally and allows for dose escalation to 95mg once daily, orally at 4 weeks if not controlled; at week 8 allows for the addition of felodipine sustained release tablet 5mg once daily, orally
Trial: NCT00739466
Drug: Liposomal Alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV in a single low dose during the index procedure (coronary stent implantation) over 2 hours
Trial: NCT00739466
Drug: Liposomal Alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV in a single high dose during the index procedure (coronary stent implantation) over 2 hours
Trial: NCT01930552
Drug: Aflibercept AVE0005
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form:Solution for infusion Route of administration: Intravenous
Trial: NCT01930552
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:Solution for infusion Route of administration: Intravenous
Trial: NCT01930552
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:Solution for infusion Route of administration: Intravenous
Trial: NCT00143533
Drug: Irinotecan, Cefpodoxime
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: See Detailed description section for treatment details.
Trial: NCT02204852
Drug: Iloprost+eptifibatide
RxNorm normalized name: Iloprost
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01669213
Drug: ramosetron
RxNorm normalized name: ramosetron
DrugBank: Ramosetron (DB09290)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: before 5 minutes spinal anesthesia, injection of ramosetron 0.3 mg
Trial: NCT01669213
Drug: ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: before 5 minutes spinal anesthesia, injection of ondansetron 8 mg
Trial: NCT01669213
Drug: ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: before 5 minutes spinal anesthesia, injection of ondansetron 4 mg
Trial: NCT02621073
Drug: VeraFlo with Prontosan
RxNorm normalized name: Primatene with ephedrine Pill
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VeraFlo device with Prontosan instillation (n=10).
Trial: NCT01516567
Drug: Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 6 courses of Dose Adjusted-EPOCH-Rituximab Rituximab 375 mg/m² i.v.: one injection at each of the 6 courses of EPOCH.
Trial: NCT02535416
Drug: ARC-520
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02535416
Drug: cetirizine
RxNorm normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02535416
Drug: diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04326764
Drug: Panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panobinostat should be taken orally once on each scheduled day at about the same time, either with or without food. Each dose of panobinostat should be taken with a cup of water.~The capsules should be swallowed as whole. If vomiting occurs during the course of treatment, no re-dosing is allowed before the next scheduled dose. If one dose is forgotten during the morning on a scheduled treatment day then the missed dose should be taken on that same day within 12 hours. After more than 12 hours, that day's dose should be withheld, and the patient should wait to take panobinostat until the next schedule treatment day. The patient should then continue treatment with the original dosing schedule.~Panobinostat will be administered at a dose of 20 mg three times weekly (TIW) every second week and will be dosed on a flat scale of mg/day and not by weight or body surface area.~Panobinostat will be dispensed as a 20 mg capsule or as two 10 mg capsules.
Trial: NCT01335529
Drug: Boceprevir, Peg-interferon alfa 2b and Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Screen period from Week-8~* Standard treatment from day 0 to week 4 (W4)~* Three-drug-regimen (Boceprevir introduction) from W4 to W8~* HCV RNA determination at W8 determines treatment group and participation duration:~  * If undetectable HCV RNA at W8, it is a complete virological response: 3 drug-regimen is continued until W48, then there is a follow-up period up to W72 and SVR analysis,~ * If HCV RNA ≤ 1000IU/mL at W8, it is an incomplete virological response. The 3-drug-regimen is continued until W72, when another analysis is done.
Trial: NCT01256762
Drug: Imetelstat sodium
RxNorm normalized name: imetelstat sodium
DrugBank: Imetelstat (DB14909)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imetelstat is administered at a dose of 300 mg/m2 on day one of a 21 day cycle.
Trial: NCT01256762
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab is administered at 15 mg/kg on day one of a 21 day cycle
Trial: NCT01256762
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel is administered at 90 mg/m2 on days one and eight of a 21 day cycle
Trial: NCT00897390
Drug: Saxagliptin
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, Oral, 2.5 mg, Once Daily, 1 week
Trial: NCT00897390
Drug: Metformin IR (glucophage)
RxNorm normalized name: metformin Oral Tablet [Glucophage]
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, Oral, 1000 mg, Once Daily, 1 week
Trial: NCT00897390
Drug: Saxagliptin + Metformin IR (FDC)
RxNorm normalized name: metformin / saxagliptin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet, Oral, Saxagliptin 2.5 mg + metformin IR 1000 mg, Once Daily, 1 Week
Trial: NCT04665531
Drug: Ropivacaine 0.2% Injectable Solution
RxNorm normalized name: ROPivacaine 0.2% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the experimental group will receive Ropivacaine 0,2% continous infusion of 5ml/h with boluses 15ml/4h by the Erector Spinae Catheter for 48 hours post-operatively.
Trial: NCT02666794
Drug: Epidural bupivacaine with vasoconstrictor 0.125%
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 ml
Trial: NCT02666794
Drug: Intrathecal hyperbaric bupivacaine solution 0.5%
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg
Trial: NCT02666794
Drug: Intrathecal morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mcg
Trial: NCT02155530
Drug: Atorvastatin 40mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 40MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: homogenous neointimal pattern at baseline OCT and randomized to atorvastatin 40 mg group
Trial: NCT01069133
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 550mg BID open-label
Trial: NCT01069133
Drug: rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 550mg PO BID
Trial: NCT00418054
Drug: Nitazoxanide plus peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00418054
Drug: Peginterferon alfa-2b
RxNorm normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02476136
Drug: paroxetine, duloxetine, fluoxetine or venlafaxine
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04689971
Drug: Vitamin B combination
RxNorm normalized name: VITAMIN B
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B combination (B1 100 mg, B2 200 mg and B12 200 mcg) tablet once daily
Trial: NCT01487993
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral administration, 500 mg daily at week 1. Every week metformin dosage increases with 500 mg, to a maximum dose of 1000 mg bid. This maximum dose will be administered till the end of the study.
Trial: NCT00686556
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beginning on Day -3 pre-transplant maintaining a level of \>200 ng/mL. CSA dosing will be monitored and altered as clinically appropriate by Pharm D or physician, and discontinue at approximately day + 180 post-transplant.
Trial: NCT00686556
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/m2/day intravenous as a 1 hour infusion for consecutive 3 days pre-transplant, total dose 75 mg/m2
Trial: NCT00686556
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Beginning on day -3, use intravenous route between days -3 and +5, followed by oral administration on Day +6 through +30, if tolerated. 15mg/kg/dose for patients \<40 kg, 3 gm/day for patients \>40 kg.
Trial: NCT02062203
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of 400 mg moxifloxacin
Trial: NCT01704703
Drug: panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab 6,0 mg/kg day 1 i.v. 60 min
Trial: NCT03054662
Drug: Implement haemostatic non substitutive care of haemophilia
RxNorm normalized name: Low-Substituted Hydroxypropyl Cellulose
DrugBank: Hydroxypropyl cellulose (DB00840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implement the use of DDAVP and antifibrinolytics in patients with haemophilia and symptomatic carriers